nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—GNRHR—GPCR ligand binding—ANXA1—lung cancer	0.000794	0.00392	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—GIPR—lung cancer	0.000791	0.0039	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—GNG11—lung cancer	0.000774	0.00382	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000768	0.00379	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—ADCY1—lung cancer	0.000767	0.00378	CbGpPWpGaD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000763	0.00376	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—APP—lung cancer	0.000752	0.00371	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—GRM8—lung cancer	0.00074	0.00365	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—COL4A2—lung cancer	0.000716	0.00353	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PTHLH—lung cancer	0.000713	0.00352	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GIPR—lung cancer	0.000698	0.00344	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—ADCY1—lung cancer	0.000696	0.00344	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PPP2R1B—lung cancer	0.000678	0.00335	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000673	0.00332	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—GRM8—lung cancer	0.000672	0.00332	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—ANXA1—lung cancer	0.00067	0.00331	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SDC4—lung cancer	0.000651	0.00321	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PTHLH—lung cancer	0.000647	0.00319	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.000641	0.00316	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—DUSP3—lung cancer	0.000638	0.00315	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—APP—lung cancer	0.000635	0.00313	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RHEB—lung cancer	0.000626	0.00309	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AXL—lung cancer	0.000616	0.00304	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—GRP—lung cancer	0.00061	0.00301	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—OXTR—lung cancer	0.00061	0.00301	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—ANXA1—lung cancer	0.000608	0.003	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GRM8—lung cancer	0.000593	0.00293	CbGpPWpGaD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.00059	0.00291	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—AVP—lung cancer	0.000585	0.00289	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—POMC—lung cancer	0.000581	0.00287	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—APP—lung cancer	0.000577	0.00285	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SKI—lung cancer	0.000575	0.00284	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—GNG11—lung cancer	0.000571	0.00282	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000569	0.00281	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—GRP—lung cancer	0.000554	0.00273	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—OXTR—lung cancer	0.000554	0.00273	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—GNG11—lung cancer	0.000518	0.00256	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ADCY1—lung cancer	0.000513	0.00253	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000511	0.00252	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PXN—lung cancer	0.000499	0.00246	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AVP—lung cancer	0.000494	0.00244	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKR1C1—lung cancer	0.000489	0.00241	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—OXTR—lung cancer	0.000489	0.00241	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GRP—lung cancer	0.000489	0.00241	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—COL4A2—lung cancer	0.000479	0.00237	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PTHLH—lung cancer	0.000477	0.00235	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GIPR—lung cancer	0.000467	0.0023	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ADCY1—lung cancer	0.000466	0.0023	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GNG11—lung cancer	0.000457	0.00226	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PPP2R1B—lung cancer	0.000454	0.00224	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—CXCL8—lung cancer	0.000449	0.00222	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AVP—lung cancer	0.000449	0.00221	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ANXA1—lung cancer	0.000449	0.00221	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SDC4—lung cancer	0.000436	0.00215	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VEGFC—lung cancer	0.000435	0.00215	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PTHLH—lung cancer	0.000433	0.00214	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	0.000428	0.00211	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—DUSP3—lung cancer	0.000427	0.00211	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—APP—lung cancer	0.000425	0.0021	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RHEB—lung cancer	0.000419	0.00207	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ADCY1—lung cancer	0.000411	0.00203	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	0.00041	0.00202	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ANXA1—lung cancer	0.000407	0.00201	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SMARCA4—lung cancer	0.000401	0.00198	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PPP2R1B—lung cancer	0.000401	0.00198	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GRM8—lung cancer	0.000397	0.00196	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000395	0.00195	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	0.00039	0.00192	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—POMC—lung cancer	0.000389	0.00192	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HSPB1—lung cancer	0.000387	0.00191	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—APP—lung cancer	0.000386	0.00191	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SKI—lung cancer	0.000385	0.0019	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTHLH—lung cancer	0.000382	0.00189	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—PIK3CA—lung cancer	0.000378	0.00187	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	0.000368	0.00182	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ANXA1—lung cancer	0.000359	0.00177	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FLT1—lung cancer	0.000348	0.00172	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CG—lung cancer	0.000345	0.0017	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NOTCH3—lung cancer	0.000341	0.00168	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—APP—lung cancer	0.000341	0.00168	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	0.000338	0.00167	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF9—lung cancer	0.000338	0.00167	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PXN—lung cancer	0.000334	0.00165	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AVP—lung cancer	0.000331	0.00163	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—POMC—lung cancer	0.000328	0.00162	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKR1C1—lung cancer	0.000327	0.00161	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—OXTR—lung cancer	0.000327	0.00161	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GRP—lung cancer	0.000327	0.00161	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JUNB—lung cancer	0.000323	0.00159	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CG—lung cancer	0.000313	0.00155	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	0.000313	0.00154	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GNG11—lung cancer	0.000306	0.00151	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CD—lung cancer	0.000303	0.0015	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—CXCL8—lung cancer	0.000301	0.00148	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AVP—lung cancer	0.0003	0.00148	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	0.0003	0.00148	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—POMC—lung cancer	0.000298	0.00147	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STK11—lung cancer	0.000293	0.00145	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFC—lung cancer	0.000292	0.00144	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6R—lung cancer	0.000291	0.00143	CbGpPWpGaD
Goserelin—Body temperature increased—Cisplatin—lung cancer	0.000285	0.000357	CcSEcCtD
Goserelin—Asthenia—Irinotecan—lung cancer	0.000285	0.000357	CcSEcCtD
Goserelin—Fatigue—Etoposide—lung cancer	0.000285	0.000357	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000284	0.000356	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—FOXO3—lung cancer	0.000283	0.0014	CbGpPWpGaD
Goserelin—Pain—Etoposide—lung cancer	0.000282	0.000354	CcSEcCtD
Goserelin—Constipation—Etoposide—lung cancer	0.000282	0.000354	CcSEcCtD
Goserelin—Dysuria—Doxorubicin—lung cancer	0.000282	0.000353	CcSEcCtD
Goserelin—Decreased appetite—Paclitaxel—lung cancer	0.000281	0.000353	CcSEcCtD
Goserelin—Dry mouth—Docetaxel—lung cancer	0.00028	0.000351	CcSEcCtD
Goserelin—Upper respiratory tract infection—Doxorubicin—lung cancer	0.00028	0.000351	CcSEcCtD
Goserelin—Haemoglobin—Methotrexate—lung cancer	0.00028	0.000351	CcSEcCtD
Goserelin—Fatigue—Paclitaxel—lung cancer	0.000279	0.00035	CcSEcCtD
Goserelin—Haemorrhage—Methotrexate—lung cancer	0.000278	0.000349	CcSEcCtD
Goserelin—Hepatitis—Methotrexate—lung cancer	0.000278	0.000349	CcSEcCtD
Goserelin—Pollakiuria—Doxorubicin—lung cancer	0.000278	0.000349	CcSEcCtD
Goserelin—Asthenia—Gemcitabine—lung cancer	0.000277	0.000348	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—MAP2K1—lung cancer	0.000277	0.00137	CbGpPWpGaD
Goserelin—Constipation—Paclitaxel—lung cancer	0.000277	0.000347	CcSEcCtD
Goserelin—Pain—Paclitaxel—lung cancer	0.000277	0.000347	CcSEcCtD
Goserelin—Confusional state—Docetaxel—lung cancer	0.000277	0.000347	CcSEcCtD
Goserelin—Pharyngitis—Methotrexate—lung cancer	0.000276	0.000346	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—PIK3CD—lung cancer	0.000275	0.00136	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ADCY1—lung cancer	0.000275	0.00136	CbGpPWpGaD
Goserelin—Urinary tract disorder—Methotrexate—lung cancer	0.000275	0.000345	CcSEcCtD
Goserelin—Photosensitivity reaction—Doxorubicin—lung cancer	0.000275	0.000345	CcSEcCtD
Goserelin—Anaphylactic shock—Docetaxel—lung cancer	0.000274	0.000344	CcSEcCtD
Goserelin—Oedema—Docetaxel—lung cancer	0.000274	0.000344	CcSEcCtD
Goserelin—Weight increased—Doxorubicin—lung cancer	0.000274	0.000344	CcSEcCtD
Goserelin—Pruritus—Gemcitabine—lung cancer	0.000274	0.000343	CcSEcCtD
Goserelin—Urethral disorder—Methotrexate—lung cancer	0.000273	0.000342	CcSEcCtD
Goserelin—Infection—Docetaxel—lung cancer	0.000273	0.000342	CcSEcCtD
Goserelin—Feeling abnormal—Etoposide—lung cancer	0.000272	0.000341	CcSEcCtD
Goserelin—Hyperglycaemia—Doxorubicin—lung cancer	0.000272	0.000341	CcSEcCtD
Goserelin—Diarrhoea—Irinotecan—lung cancer	0.000272	0.000341	CcSEcCtD
Goserelin—Pneumonia—Doxorubicin—lung cancer	0.00027	0.000339	CcSEcCtD
Goserelin—Gastrointestinal pain—Etoposide—lung cancer	0.00027	0.000339	CcSEcCtD
Goserelin—Shock—Docetaxel—lung cancer	0.00027	0.000339	CcSEcCtD
Goserelin—Nervous system disorder—Docetaxel—lung cancer	0.000269	0.000337	CcSEcCtD
Goserelin—Thrombocytopenia—Docetaxel—lung cancer	0.000269	0.000337	CcSEcCtD
Goserelin—Drowsiness—Doxorubicin—lung cancer	0.000268	0.000337	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SMARCA4—lung cancer	0.000268	0.00132	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PPP2R1B—lung cancer	0.000268	0.00132	CbGpPWpGaD
Goserelin—Tachycardia—Docetaxel—lung cancer	0.000268	0.000336	CcSEcCtD
Goserelin—Feeling abnormal—Paclitaxel—lung cancer	0.000267	0.000335	CcSEcCtD
Goserelin—Skin disorder—Docetaxel—lung cancer	0.000266	0.000334	CcSEcCtD
Goserelin—Hypersensitivity—Cisplatin—lung cancer	0.000265	0.000333	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—AVP—lung cancer	0.000265	0.00131	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Paclitaxel—lung cancer	0.000265	0.000332	CcSEcCtD
Goserelin—Diarrhoea—Gemcitabine—lung cancer	0.000265	0.000332	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CB—lung cancer	0.000264	0.0013	CbGpPWpGaD
Goserelin—Renal failure—Doxorubicin—lung cancer	0.000264	0.000331	CcSEcCtD
Goserelin—Dizziness—Irinotecan—lung cancer	0.000262	0.000329	CcSEcCtD
Goserelin—Urticaria—Etoposide—lung cancer	0.000262	0.000329	CcSEcCtD
Goserelin—Jaundice—Doxorubicin—lung cancer	0.000262	0.000328	CcSEcCtD
Goserelin—Anorexia—Docetaxel—lung cancer	0.000262	0.000328	CcSEcCtD
Goserelin—Abdominal pain—Etoposide—lung cancer	0.000261	0.000327	CcSEcCtD
Goserelin—Body temperature increased—Etoposide—lung cancer	0.000261	0.000327	CcSEcCtD
Goserelin—Urinary tract infection—Doxorubicin—lung cancer	0.000261	0.000327	CcSEcCtD
Goserelin—Eye disorder—Methotrexate—lung cancer	0.00026	0.000326	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HSPB1—lung cancer	0.000259	0.00128	CbGpPWpGaD
Goserelin—Asthenia—Cisplatin—lung cancer	0.000259	0.000324	CcSEcCtD
Goserelin—Cardiac disorder—Methotrexate—lung cancer	0.000258	0.000324	CcSEcCtD
Goserelin—Sweating—Doxorubicin—lung cancer	0.000257	0.000323	CcSEcCtD
Goserelin—Urticaria—Paclitaxel—lung cancer	0.000257	0.000322	CcSEcCtD
Goserelin—Hypotension—Docetaxel—lung cancer	0.000256	0.000322	CcSEcCtD
Goserelin—Haematuria—Doxorubicin—lung cancer	0.000256	0.000321	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PTHLH—lung cancer	0.000256	0.00126	CbGpPWpGaD
Goserelin—Abdominal pain—Paclitaxel—lung cancer	0.000256	0.000321	CcSEcCtD
Goserelin—Body temperature increased—Paclitaxel—lung cancer	0.000256	0.000321	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IGF1R—lung cancer	0.000255	0.00126	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CXCL8—lung cancer	0.000254	0.00125	CbGpPWpGaD
Goserelin—Epistaxis—Doxorubicin—lung cancer	0.000253	0.000318	CcSEcCtD
Goserelin—Angiopathy—Methotrexate—lung cancer	0.000253	0.000317	CcSEcCtD
Goserelin—Vomiting—Irinotecan—lung cancer	0.000252	0.000316	CcSEcCtD
Goserelin—Sinusitis—Doxorubicin—lung cancer	0.000252	0.000316	CcSEcCtD
Goserelin—Immune system disorder—Methotrexate—lung cancer	0.000251	0.000315	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—HES1—lung cancer	0.000251	0.00124	CbGpPWpGaD
Goserelin—Rash—Irinotecan—lung cancer	0.00025	0.000314	CcSEcCtD
Goserelin—Dermatitis—Irinotecan—lung cancer	0.00025	0.000314	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Docetaxel—lung cancer	0.00025	0.000313	CcSEcCtD
Goserelin—Chills—Methotrexate—lung cancer	0.00025	0.000313	CcSEcCtD
Goserelin—Headache—Irinotecan—lung cancer	0.000249	0.000312	CcSEcCtD
Goserelin—Insomnia—Docetaxel—lung cancer	0.000248	0.000311	CcSEcCtD
Goserelin—Diarrhoea—Cisplatin—lung cancer	0.000247	0.000309	CcSEcCtD
Goserelin—Paraesthesia—Docetaxel—lung cancer	0.000246	0.000309	CcSEcCtD
Goserelin—Alopecia—Methotrexate—lung cancer	0.000246	0.000308	CcSEcCtD
Goserelin—Vomiting—Gemcitabine—lung cancer	0.000246	0.000308	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—RAF1—lung cancer	0.000246	0.00121	CbGpPWpGaD
Goserelin—Dyspnoea—Docetaxel—lung cancer	0.000245	0.000307	CcSEcCtD
Goserelin—Somnolence—Docetaxel—lung cancer	0.000244	0.000306	CcSEcCtD
Goserelin—Mental disorder—Methotrexate—lung cancer	0.000244	0.000306	CcSEcCtD
Goserelin—Rash—Gemcitabine—lung cancer	0.000244	0.000306	CcSEcCtD
Goserelin—Dermatitis—Gemcitabine—lung cancer	0.000244	0.000305	CcSEcCtD
Goserelin—Hypersensitivity—Etoposide—lung cancer	0.000243	0.000305	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—IL2—lung cancer	0.000243	0.0012	CbGpPWpGaD
Goserelin—Erythema—Methotrexate—lung cancer	0.000242	0.000304	CcSEcCtD
Goserelin—Malnutrition—Methotrexate—lung cancer	0.000242	0.000304	CcSEcCtD
Goserelin—Haemoglobin—Doxorubicin—lung cancer	0.000242	0.000304	CcSEcCtD
Goserelin—Headache—Gemcitabine—lung cancer	0.000242	0.000304	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—lung cancer	0.000242	0.000303	CcSEcCtD
Goserelin—Dyspepsia—Docetaxel—lung cancer	0.000241	0.000303	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—lung cancer	0.000241	0.000302	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—lung cancer	0.000241	0.000302	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ANXA1—lung cancer	0.000241	0.00119	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CB—lung cancer	0.00024	0.00118	CbGpPWpGaD
Goserelin—Pharyngitis—Doxorubicin—lung cancer	0.000239	0.0003	CcSEcCtD
Goserelin—Decreased appetite—Docetaxel—lung cancer	0.000238	0.000299	CcSEcCtD
Goserelin—Hypersensitivity—Paclitaxel—lung cancer	0.000238	0.000299	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—lung cancer	0.000238	0.000298	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—lung cancer	0.000237	0.000298	CcSEcCtD
Goserelin—Asthenia—Etoposide—lung cancer	0.000237	0.000297	CcSEcCtD
Goserelin—Fatigue—Docetaxel—lung cancer	0.000237	0.000297	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—lung cancer	0.000236	0.000296	CcSEcCtD
Goserelin—Nausea—Irinotecan—lung cancer	0.000236	0.000296	CcSEcCtD
Goserelin—Constipation—Docetaxel—lung cancer	0.000235	0.000294	CcSEcCtD
Goserelin—Pain—Docetaxel—lung cancer	0.000235	0.000294	CcSEcCtD
Goserelin—Back pain—Methotrexate—lung cancer	0.000234	0.000294	CcSEcCtD
Goserelin—Pruritus—Etoposide—lung cancer	0.000234	0.000293	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FLT1—lung cancer	0.000233	0.00115	CbGpPWpGaD
Goserelin—Asthenia—Paclitaxel—lung cancer	0.000232	0.000291	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CG—lung cancer	0.000231	0.00114	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CXCL8—lung cancer	0.000231	0.00114	CbGpPWpGaD
Goserelin—Nausea—Gemcitabine—lung cancer	0.00023	0.000288	CcSEcCtD
Goserelin—Vomiting—Cisplatin—lung cancer	0.000229	0.000287	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—ERBB3—lung cancer	0.000229	0.00113	CbGpPWpGaD
Goserelin—Pruritus—Paclitaxel—lung cancer	0.000229	0.000287	CcSEcCtD
Goserelin—Vision blurred—Methotrexate—lung cancer	0.000228	0.000286	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—NOTCH3—lung cancer	0.000228	0.00113	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—APP—lung cancer	0.000228	0.00113	CbGpPWpGaD
Goserelin—Rash—Cisplatin—lung cancer	0.000227	0.000285	CcSEcCtD
Goserelin—Dermatitis—Cisplatin—lung cancer	0.000227	0.000285	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FGF9—lung cancer	0.000226	0.00112	CbGpPWpGaD
Goserelin—Feeling abnormal—Docetaxel—lung cancer	0.000226	0.000284	CcSEcCtD
Goserelin—Diarrhoea—Etoposide—lung cancer	0.000226	0.000283	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—lung cancer	0.000225	0.000282	CcSEcCtD
Goserelin—Ill-defined disorder—Methotrexate—lung cancer	0.000225	0.000282	CcSEcCtD
Goserelin—Gastrointestinal pain—Docetaxel—lung cancer	0.000224	0.000281	CcSEcCtD
Goserelin—Anaemia—Methotrexate—lung cancer	0.000224	0.000281	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—lung cancer	0.000224	0.000281	CcSEcCtD
Goserelin—Diarrhoea—Paclitaxel—lung cancer	0.000221	0.000278	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—IL2—lung cancer	0.00022	0.00109	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—POMC—lung cancer	0.00022	0.00108	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TERT—lung cancer	0.00022	0.00108	CbGpPWpGaD
Goserelin—Angiopathy—Doxorubicin—lung cancer	0.000219	0.000274	CcSEcCtD
Goserelin—Malaise—Methotrexate—lung cancer	0.000218	0.000274	CcSEcCtD
Goserelin—Dizziness—Etoposide—lung cancer	0.000218	0.000274	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—lung cancer	0.000218	0.000273	CcSEcCtD
Goserelin—Abdominal pain—Docetaxel—lung cancer	0.000217	0.000272	CcSEcCtD
Goserelin—Body temperature increased—Docetaxel—lung cancer	0.000217	0.000272	CcSEcCtD
Goserelin—Leukopenia—Methotrexate—lung cancer	0.000217	0.000272	CcSEcCtD
Goserelin—Chills—Doxorubicin—lung cancer	0.000216	0.000271	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—JUNB—lung cancer	0.000216	0.00107	CbGpPWpGaD
Goserelin—Arrhythmia—Doxorubicin—lung cancer	0.000215	0.00027	CcSEcCtD
Goserelin—Dizziness—Paclitaxel—lung cancer	0.000214	0.000268	CcSEcCtD
Goserelin—Nausea—Cisplatin—lung cancer	0.000214	0.000268	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—FGFR1—lung cancer	0.000213	0.00105	CbGpPWpGaD
Goserelin—Alopecia—Doxorubicin—lung cancer	0.000213	0.000267	CcSEcCtD
Goserelin—Cough—Methotrexate—lung cancer	0.000211	0.000265	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—lung cancer	0.000211	0.000265	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—HIF1A—lung cancer	0.00021	0.00104	CbGpPWpGaD
Goserelin—Convulsion—Methotrexate—lung cancer	0.00021	0.000263	CcSEcCtD
Goserelin—Vomiting—Etoposide—lung cancer	0.00021	0.000263	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—lung cancer	0.00021	0.000263	CcSEcCtD
Goserelin—Erythema—Doxorubicin—lung cancer	0.00021	0.000263	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CG—lung cancer	0.00021	0.00103	CbGpPWpGaD
Goserelin—Rash—Etoposide—lung cancer	0.000208	0.000261	CcSEcCtD
Goserelin—Dermatitis—Etoposide—lung cancer	0.000208	0.000261	CcSEcCtD
Goserelin—Headache—Etoposide—lung cancer	0.000207	0.000259	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—lung cancer	0.000207	0.000259	CcSEcCtD
Goserelin—Arthralgia—Methotrexate—lung cancer	0.000206	0.000259	CcSEcCtD
Goserelin—Chest pain—Methotrexate—lung cancer	0.000206	0.000259	CcSEcCtD
Goserelin—Myalgia—Methotrexate—lung cancer	0.000206	0.000259	CcSEcCtD
Goserelin—Tension—Doxorubicin—lung cancer	0.000206	0.000258	CcSEcCtD
Goserelin—Vomiting—Paclitaxel—lung cancer	0.000206	0.000258	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000205	0.000257	CcSEcCtD
Goserelin—Rash—Paclitaxel—lung cancer	0.000204	0.000256	CcSEcCtD
Goserelin—Dermatitis—Paclitaxel—lung cancer	0.000204	0.000256	CcSEcCtD
Goserelin—Discomfort—Methotrexate—lung cancer	0.000204	0.000256	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—lung cancer	0.000204	0.000256	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CD—lung cancer	0.000203	0.001	CbGpPWpGaD
Goserelin—Back pain—Doxorubicin—lung cancer	0.000203	0.000255	CcSEcCtD
Goserelin—Headache—Paclitaxel—lung cancer	0.000203	0.000254	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—APOA1—lung cancer	0.000203	0.001	CbGpPWpGaD
Goserelin—Hypersensitivity—Docetaxel—lung cancer	0.000202	0.000254	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—lung cancer	0.000202	0.000253	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—KDR—lung cancer	0.000201	0.000991	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—POMC—lung cancer	0.0002	0.000985	CbGpPWpGaD
Goserelin—Confusional state—Methotrexate—lung cancer	0.000199	0.00025	CcSEcCtD
Goserelin—Anaphylactic shock—Methotrexate—lung cancer	0.000198	0.000248	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—lung cancer	0.000198	0.000248	CcSEcCtD
Goserelin—Asthenia—Docetaxel—lung cancer	0.000197	0.000247	CcSEcCtD
Goserelin—Infection—Methotrexate—lung cancer	0.000196	0.000246	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—STK11—lung cancer	0.000196	0.000968	CbGpPWpGaD
Goserelin—Nausea—Etoposide—lung cancer	0.000196	0.000246	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—IL6R—lung cancer	0.000195	0.000961	CbGpPWpGaD
Goserelin—Ill-defined disorder—Doxorubicin—lung cancer	0.000195	0.000244	CcSEcCtD
Goserelin—Pruritus—Docetaxel—lung cancer	0.000194	0.000243	CcSEcCtD
Goserelin—Nervous system disorder—Methotrexate—lung cancer	0.000194	0.000243	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—lung cancer	0.000194	0.000243	CcSEcCtD
Goserelin—Thrombocytopenia—Methotrexate—lung cancer	0.000194	0.000243	CcSEcCtD
Goserelin—Nausea—Paclitaxel—lung cancer	0.000192	0.000241	CcSEcCtD
Goserelin—Skin disorder—Methotrexate—lung cancer	0.000192	0.000241	CcSEcCtD
Goserelin—Hyperhidrosis—Methotrexate—lung cancer	0.000191	0.00024	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FOXO3—lung cancer	0.000189	0.000934	CbGpPWpGaD
Goserelin—Malaise—Doxorubicin—lung cancer	0.000189	0.000237	CcSEcCtD
Goserelin—Anorexia—Methotrexate—lung cancer	0.000188	0.000236	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—lung cancer	0.000188	0.000236	CcSEcCtD
Goserelin—Diarrhoea—Docetaxel—lung cancer	0.000188	0.000235	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—MAP2K1—lung cancer	0.000186	0.000915	CbGpPWpGaD
Goserelin—Palpitations—Doxorubicin—lung cancer	0.000185	0.000233	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—APC—lung cancer	0.000185	0.000913	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CG—lung cancer	0.000185	0.000913	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KIT—lung cancer	0.000185	0.000913	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—NRAS—lung cancer	0.000185	0.000913	CbGpPWpGaD
Goserelin—Hypotension—Methotrexate—lung cancer	0.000185	0.000232	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CD—lung cancer	0.000184	0.000909	CbGpPWpGaD
Goserelin—Cough—Doxorubicin—lung cancer	0.000183	0.00023	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—EGF—lung cancer	0.000183	0.000902	CbGpPWpGaD
Goserelin—Convulsion—Doxorubicin—lung cancer	0.000182	0.000228	CcSEcCtD
Goserelin—Dizziness—Docetaxel—lung cancer	0.000181	0.000228	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—lung cancer	0.000181	0.000227	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Methotrexate—lung cancer	0.00018	0.000226	CcSEcCtD
Goserelin—Insomnia—Methotrexate—lung cancer	0.000179	0.000224	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—lung cancer	0.000179	0.000224	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—lung cancer	0.000179	0.000224	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—lung cancer	0.000179	0.000224	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—lung cancer	0.000178	0.000223	CcSEcCtD
Goserelin—Paraesthesia—Methotrexate—lung cancer	0.000178	0.000223	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—AVP—lung cancer	0.000177	0.000875	CbGpPWpGaD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000177	0.000222	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—MAPK3—lung cancer	0.000177	0.000874	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CB—lung cancer	0.000177	0.000873	CbGpPWpGaD
Goserelin—Discomfort—Doxorubicin—lung cancer	0.000176	0.000221	CcSEcCtD
Goserelin—Dyspnoea—Methotrexate—lung cancer	0.000176	0.000221	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—POMC—lung cancer	0.000176	0.000869	CbGpPWpGaD
Goserelin—Somnolence—Methotrexate—lung cancer	0.000176	0.00022	CcSEcCtD
Goserelin—Dry mouth—Doxorubicin—lung cancer	0.000175	0.000219	CcSEcCtD
Goserelin—Vomiting—Docetaxel—lung cancer	0.000174	0.000219	CcSEcCtD
Goserelin—Dyspepsia—Methotrexate—lung cancer	0.000174	0.000218	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—BRAF—lung cancer	0.000174	0.000858	CbGpPWpGaD
Goserelin—Rash—Docetaxel—lung cancer	0.000173	0.000217	CcSEcCtD
Goserelin—Dermatitis—Docetaxel—lung cancer	0.000173	0.000217	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—lung cancer	0.000173	0.000217	CcSEcCtD
Goserelin—Decreased appetite—Methotrexate—lung cancer	0.000172	0.000216	CcSEcCtD
Goserelin—Headache—Docetaxel—lung cancer	0.000172	0.000216	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL6R—lung cancer	0.000172	0.000848	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CREBBP—lung cancer	0.000172	0.000846	CbGpPWpGaD
Goserelin—Anaphylactic shock—Doxorubicin—lung cancer	0.000171	0.000215	CcSEcCtD
Goserelin—Oedema—Doxorubicin—lung cancer	0.000171	0.000215	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IGF1R—lung cancer	0.000171	0.000843	CbGpPWpGaD
Goserelin—Fatigue—Methotrexate—lung cancer	0.00017	0.000214	CcSEcCtD
Goserelin—Infection—Doxorubicin—lung cancer	0.00017	0.000213	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—CXCL8—lung cancer	0.00017	0.000839	CbGpPWpGaD
Goserelin—Pain—Methotrexate—lung cancer	0.000169	0.000212	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—EGFR—lung cancer	0.000169	0.000832	CbGpPWpGaD
Goserelin—Shock—Doxorubicin—lung cancer	0.000168	0.000211	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—lung cancer	0.000168	0.000211	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HES1—lung cancer	0.000168	0.000828	CbGpPWpGaD
Goserelin—Thrombocytopenia—Doxorubicin—lung cancer	0.000168	0.00021	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—lung cancer	0.000167	0.00021	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—lung cancer	0.000166	0.000209	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—lung cancer	0.000166	0.000208	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—RAF1—lung cancer	0.000165	0.000812	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAP2K1—lung cancer	0.000164	0.000808	CbGpPWpGaD
Goserelin—Anorexia—Doxorubicin—lung cancer	0.000163	0.000205	CcSEcCtD
Goserelin—Nausea—Docetaxel—lung cancer	0.000163	0.000204	CcSEcCtD
Goserelin—Feeling abnormal—Methotrexate—lung cancer	0.000163	0.000204	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CD—lung cancer	0.000163	0.000803	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2—lung cancer	0.000162	0.000802	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Methotrexate—lung cancer	0.000162	0.000203	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—lung cancer	0.000161	0.000795	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CB—lung cancer	0.000161	0.000793	CbGpPWpGaD
Goserelin—Hypotension—Doxorubicin—lung cancer	0.00016	0.000201	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—KRAS—lung cancer	0.000159	0.000786	CbGpPWpGaD
Goserelin—Urticaria—Methotrexate—lung cancer	0.000157	0.000197	CcSEcCtD
Goserelin—Body temperature increased—Methotrexate—lung cancer	0.000156	0.000196	CcSEcCtD
Goserelin—Abdominal pain—Methotrexate—lung cancer	0.000156	0.000196	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000156	0.000196	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—lung cancer	0.000155	0.000194	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—CXCL8—lung cancer	0.000154	0.000762	CbGpPWpGaD
Goserelin—Paraesthesia—Doxorubicin—lung cancer	0.000154	0.000193	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ERBB3—lung cancer	0.000153	0.000757	CbGpPWpGaD
Goserelin—Dyspnoea—Doxorubicin—lung cancer	0.000153	0.000191	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—lung cancer	0.000152	0.000191	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—lung cancer	0.000151	0.000189	CcSEcCtD
Goserelin—Decreased appetite—Doxorubicin—lung cancer	0.000149	0.000187	CcSEcCtD
Goserelin—Fatigue—Doxorubicin—lung cancer	0.000148	0.000185	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—IL2—lung cancer	0.000148	0.000728	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TERT—lung cancer	0.000147	0.000725	CbGpPWpGaD
Goserelin—Constipation—Doxorubicin—lung cancer	0.000146	0.000184	CcSEcCtD
Goserelin—Pain—Doxorubicin—lung cancer	0.000146	0.000184	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—lung cancer	0.000146	0.000722	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MDM2—lung cancer	0.000146	0.000719	CbGpPWpGaD
Goserelin—Hypersensitivity—Methotrexate—lung cancer	0.000146	0.000183	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—RAF1—lung cancer	0.000145	0.000716	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ERBB2—lung cancer	0.000144	0.000709	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGFR1—lung cancer	0.000143	0.000704	CbGpPWpGaD
Goserelin—Asthenia—Methotrexate—lung cancer	0.000142	0.000178	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MTOR—lung cancer	0.000142	0.000699	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CB—lung cancer	0.000142	0.000699	CbGpPWpGaD
Goserelin—Feeling abnormal—Doxorubicin—lung cancer	0.000141	0.000177	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HIF1A—lung cancer	0.000141	0.000694	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Doxorubicin—lung cancer	0.00014	0.000176	CcSEcCtD
Goserelin—Pruritus—Methotrexate—lung cancer	0.00014	0.000175	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CXCL8—lung cancer	0.000136	0.000672	CbGpPWpGaD
Goserelin—Urticaria—Doxorubicin—lung cancer	0.000136	0.000171	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—APOA1—lung cancer	0.000136	0.000669	CbGpPWpGaD
Goserelin—Body temperature increased—Doxorubicin—lung cancer	0.000135	0.00017	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—lung cancer	0.000135	0.00017	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—HRAS—lung cancer	0.000135	0.000668	CbGpPWpGaD
Goserelin—Diarrhoea—Methotrexate—lung cancer	0.000135	0.00017	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—KDR—lung cancer	0.000134	0.000663	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—lung cancer	0.000132	0.000649	CbGpPWpGaD
Goserelin—Dizziness—Methotrexate—lung cancer	0.000131	0.000164	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CASP3—lung cancer	0.00013	0.000643	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL2—lung cancer	0.00013	0.000642	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6—lung cancer	0.00013	0.000639	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCND1—lung cancer	0.000127	0.000626	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JUN—lung cancer	0.000127	0.000625	CbGpPWpGaD
Goserelin—Hypersensitivity—Doxorubicin—lung cancer	0.000126	0.000158	CcSEcCtD
Goserelin—Vomiting—Methotrexate—lung cancer	0.000126	0.000158	CcSEcCtD
Goserelin—Rash—Methotrexate—lung cancer	0.000125	0.000156	CcSEcCtD
Goserelin—Dermatitis—Methotrexate—lung cancer	0.000125	0.000156	CcSEcCtD
Goserelin—Headache—Methotrexate—lung cancer	0.000124	0.000155	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—APC—lung cancer	0.000124	0.000611	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CG—lung cancer	0.000124	0.000611	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KIT—lung cancer	0.000124	0.000611	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—NRAS—lung cancer	0.000124	0.000611	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MMP9—lung cancer	0.000123	0.000608	CbGpPWpGaD
Goserelin—Asthenia—Doxorubicin—lung cancer	0.000123	0.000154	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CDKN1A—lung cancer	0.000123	0.000606	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTEN—lung cancer	0.000122	0.000604	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGF—lung cancer	0.000122	0.000604	CbGpPWpGaD
Goserelin—Pruritus—Doxorubicin—lung cancer	0.000121	0.000152	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—AKT1—lung cancer	0.00012	0.00059	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—MAPK3—lung cancer	0.000119	0.000585	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—POMC—lung cancer	0.000118	0.000582	CbGpPWpGaD
Goserelin—Nausea—Methotrexate—lung cancer	0.000117	0.000147	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—lung cancer	0.000117	0.000147	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—EP300—lung cancer	0.000117	0.000576	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BRAF—lung cancer	0.000116	0.000574	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6R—lung cancer	0.000115	0.000567	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CREBBP—lung cancer	0.000115	0.000567	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SRC—lung cancer	0.000114	0.000561	CbGpPWpGaD
Goserelin—Dizziness—Doxorubicin—lung cancer	0.000113	0.000142	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—EGFR—lung cancer	0.000113	0.000557	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VEGFA—lung cancer	0.000111	0.000546	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAP2K1—lung cancer	0.00011	0.000541	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT3—lung cancer	0.00011	0.000541	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NRAS—lung cancer	0.000109	0.000539	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CD—lung cancer	0.000109	0.000537	CbGpPWpGaD
Goserelin—Vomiting—Doxorubicin—lung cancer	0.000109	0.000137	CcSEcCtD
Goserelin—Rash—Doxorubicin—lung cancer	0.000108	0.000135	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—lung cancer	0.000108	0.000135	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—lung cancer	0.000108	0.000532	CbGpPWpGaD
Goserelin—Headache—Doxorubicin—lung cancer	0.000107	0.000135	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—KRAS—lung cancer	0.000107	0.000526	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK3—lung cancer	0.000105	0.000516	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MYC—lung cancer	0.000102	0.000502	CbGpPWpGaD
Goserelin—Nausea—Doxorubicin—lung cancer	0.000102	0.000128	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—EGFR—lung cancer	9.96e-05	0.000491	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—lung cancer	9.79e-05	0.000483	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MDM2—lung cancer	9.75e-05	0.000481	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RAF1—lung cancer	9.72e-05	0.00048	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ERBB2—lung cancer	9.62e-05	0.000475	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MTOR—lung cancer	9.49e-05	0.000468	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CB—lung cancer	9.49e-05	0.000468	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KRAS—lung cancer	9.41e-05	0.000464	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL8—lung cancer	9.12e-05	0.00045	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—HRAS—lung cancer	9.06e-05	0.000447	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—lung cancer	8.81e-05	0.000435	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CASP3—lung cancer	8.73e-05	0.000431	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL2—lung cancer	8.72e-05	0.00043	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6—lung cancer	8.67e-05	0.000428	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—lung cancer	8.64e-05	0.000426	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCND1—lung cancer	8.5e-05	0.000419	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JUN—lung cancer	8.48e-05	0.000418	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—lung cancer	8.36e-05	0.000413	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MMP9—lung cancer	8.25e-05	0.000407	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN1A—lung cancer	8.22e-05	0.000406	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTEN—lung cancer	8.2e-05	0.000405	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AKT1—lung cancer	8e-05	0.000395	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HRAS—lung cancer	7.99e-05	0.000395	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EP300—lung cancer	7.82e-05	0.000386	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL6—lung cancer	7.65e-05	0.000378	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SRC—lung cancer	7.6e-05	0.000375	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFA—lung cancer	7.41e-05	0.000365	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT3—lung cancer	7.33e-05	0.000362	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NRAS—lung cancer	7.32e-05	0.000361	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKT1—lung cancer	7.06e-05	0.000348	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK3—lung cancer	7.01e-05	0.000346	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MYC—lung cancer	6.81e-05	0.000336	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGFR—lung cancer	6.67e-05	0.000329	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KRAS—lung cancer	6.3e-05	0.000311	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—lung cancer	5.78e-05	0.000285	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—lung cancer	5.6e-05	0.000276	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HRAS—lung cancer	5.35e-05	0.000264	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6—lung cancer	5.12e-05	0.000253	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT1—lung cancer	4.73e-05	0.000233	CbGpPWpGaD
